This study is looking at people with asthma that is not well controlled, specifically those with moderate to severe asthma. Asthma is a condition where the airways in the lungs become narrow and swollen, making it difficult to breathe. The treatment being tested is called Brenipatide, which is also known by its code name LY3537031. This medication works by acting on certain receptors in the body that affect how the body handles sugar and may help reduce inflammation in the airways. Some people in the study will receive Brenipatide while others will receive placebo. The medication is given as an injection under the skin using a pre-filled syringe.
The purpose of the study is to find out if Brenipatide can help reduce severe asthma attacks compared to placebo. A severe asthma attack, also called an exacerbation, is when asthma symptoms suddenly get much worse and may require treatment with oral steroids or even a hospital visit. The study will measure how many severe asthma attacks happen over the course of the treatment period.
The study will last for 52 weeks, which is about one year. People taking part will be randomly assigned to receive either Brenipatide or placebo, and neither they nor their doctors will know which treatment they are getting during the study. Throughout the study, doctors will monitor how well the treatment works and check for any side effects. To join this study, people must have been diagnosed with asthma and have been taking asthma controller medication for at least 12 months, and they must have had at least one severe asthma attack that required oral steroid treatment in the past year.
France 
Germany 
Poland 
The Netherlands 
